Related Experiment Video
Updated: Apr 22, 2026
04:33
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
1.8K
Insomnia comorbid to severe psychiatric illness
Adriane M Soehner1, Katherine A Kaplan2, Allison G Harvey1
1Department of Psychology, University of California, Berkeley.
Sleep Medicine Clinics
|October 11, 2014
Summary
Sleep disturbances significantly worsen psychiatric disorders like bipolar disorder and schizophrenia, often persisting even after treatment. Addressing sleep issues is crucial for improving patient outcomes and function.
Area of Science:
- Psychiatry
- Sleep Medicine
- Neuroscience
Background:
- Sleep disturbances are common in psychiatric illnesses, negatively impacting disorder course and function.
- Insomnia and other sleep issues frequently persist despite successful psychiatric treatment or stabilization.
Purpose of the Study:
- To review the role of sleep disturbances and altered sleep architecture in bipolar disorder and schizophrenia.
- To discuss current treatments for insomnia in these severe mental illness populations.
- To explore adaptations of Cognitive Behavioral Therapy for insomnia (CBT-I) for severe mental illness.
Main Methods:
- Literature review focusing on sleep disturbances in bipolar disorder and schizophrenia.
- Analysis of the relationship between sleep, symptom status, functional impairment, and quality of life.
- Examination of existing pharmacological and psychological treatment evidence.
Main Results:
- Sleep disturbances and altered sleep architecture are integral to the course of bipolar disorder and schizophrenia.
- Insomnia often remains unresolved even with effective psychiatric care.
- Evidence for pharmacological and psychological interventions is presented, with a focus on CBT-I adaptations.
Conclusions:
- Sleep disturbances significantly impact severe mental illnesses, affecting symptoms, function, and quality of life.
- Targeting sleep problems, including adapting CBT-I, is essential for comprehensive management of bipolar disorder and schizophrenia.
- Further research is needed to optimize sleep interventions for these populations.
More Related Videos
05:59Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
2.9K
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
5.3K
Related Concept Videos
01:27Insomnia
614
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
614
01:19Management of Insomnia
761
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
761
01:14CNS Depressants: Barbiturates and Benzodiazepines
1.8K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.8K
01:24Substance Use Disorders Affecting Sleep
599
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
599
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
942
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
942
01:26Psychosis: Goals of Pharmacotherapy
686
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
686